Spatial Multi-Omics Integration for Neurodegeneration

Spatial Multi-Omics Integration for Neurodegeneration

Overview

Spatial multi-omics represents a transformative approach in neurodegenerative disease research, enabling the simultaneous mapping of gene expression, protein abundance, and metabolic states within the native tissue architecture. Unlike traditional bulk or single-cell approaches, spatial multi-omics preserves the critical contextual information of where molecules reside relative to pathological lesions, cell types, and anatomical structures[@chen2024].

This synthesis provides a comprehensive analysis of spatial multi-omics technologies and their application to Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and related disorders. The integration of spatial transcriptomics, proteomics, and metabolomics offers unprecedented resolution for understanding the spatial heterogeneity of neurodegeneration, identifying cell-type specific vulnerabilities, and discovering region-targeted therapeutic approaches.

This synthesis complements our [Multi-Omics Integration Neurodegeneration](/mechanisms/multi-omics-integration-neurodegeneration), [Single-Cell Genomics Neurodegeneration](/mechanisms/single-cell-genomics-neurodegeneration), and [Spatial Transcriptomics PSP](/mechanisms/psp-spatial-transcriptomics) pages by providing an integrated framework for combining multiple spatial modalities.

The Spatial Multi-Omics Revolution

Why Spatial Matters in Neurodegeneration

Neurodegenerative diseases exhibit profound spatial heterogeneity:

Spatial Multi-Omics Integration for Neurodegeneration

Overview

Spatial multi-omics represents a transformative approach in neurodegenerative disease research, enabling the simultaneous mapping of gene expression, protein abundance, and metabolic states within the native tissue architecture. Unlike traditional bulk or single-cell approaches, spatial multi-omics preserves the critical contextual information of where molecules reside relative to pathological lesions, cell types, and anatomical structures[@chen2024].

This synthesis provides a comprehensive analysis of spatial multi-omics technologies and their application to Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and related disorders. The integration of spatial transcriptomics, proteomics, and metabolomics offers unprecedented resolution for understanding the spatial heterogeneity of neurodegeneration, identifying cell-type specific vulnerabilities, and discovering region-targeted therapeutic approaches.

This synthesis complements our [Multi-Omics Integration Neurodegeneration](/mechanisms/multi-omics-integration-neurodegeneration), [Single-Cell Genomics Neurodegeneration](/mechanisms/single-cell-genomics-neurodegeneration), and [Spatial Transcriptomics PSP](/mechanisms/psp-spatial-transcriptomics) pages by providing an integrated framework for combining multiple spatial modalities.

The Spatial Multi-Omics Revolution

Why Spatial Matters in Neurodegeneration

Neurodegenerative diseases exhibit profound spatial heterogeneity:

| Disease | Regional Vulnerability | Pathological Gradient |
|---------|----------------------|---------------------|
| AD | Entorhinal cortex → Hippocampus → Neocortex | Aβ plaques follow characteristic laminar pattern |
| PD | Substantia nigra pars compacta → Striatum → Cortex | α-Syn spreads along neural circuits |
| ALS | Motor cortex → Spinal cord → Bulbar regions | TDP-43 pathology shows rostral-caudal gradient |
| FTD | Frontal/Temporal cortex → Subcortical structures | Region-specific atrophy patterns |

Traditional bulk RNA-seq loses this spatial information, while single-cell RNA-seq dissociates cells from their native context. Spatial multi-omics bridges this gap by measuring molecular features directly within intact tissue sections[@smith2024].

Technology Platforms

| Platform | Modality | Resolution | Sensitivity | Throughput |
|----------|----------|------------|-------------|------------|
| Visium (10x) | Transcriptomics | 55μm spots | Moderate | High |
| CosMx SMI | Transcriptomics | Single cell | High | Medium |
| Xenium | Transcriptomics | Single cell | High | High |
| MIBI-TOF | Proteomics | 0.5-1μm | High | Medium |
| IMC | Proteomics | 1μm | High | Medium |
| MALDI MSI | Metabolomics | 10-100μm | Moderate | Medium |
| AFADESI MSI | Metabolomics | 40μm | High | Medium |
| CODEX | Proteomics + Imaging | Single cell | High | High |

Spatial Transcriptomics: Mapping Gene Expression in Situ

Alzheimer's Disease Applications

Spatial transcriptomics has revealed previously unrecognized spatial organization of AD pathophysiology[@chen2024]:

Key Findings:

Parkinson's Disease Applications

| Brain Region | Spatial Finding | Disease Relevance |
|--------------|-----------------|-------------------|
| Substantia nigra | Dopaminergic neuron loss spatially confined | Cell-type vulnerability |
| Locus coeruleus | Noradrenergic neuron involvement early | Non-motor symptoms |
| Enteric nervous system | α-Syn in gut wall early | Prodromal marker |
| Olfactory bulb | Olfactory neuron pathology early | Anosmia correlation |

ALS Applications

Spatial transcriptomics of ALS motor cortex reveals[@lee2025]:

• Layer-specific degeneration in upper motor neurons
• Astrocyte reactivity gradients around surviving neurons
• Microglial activation hotspots near vacuolated regions
• RNA metabolism dysregulation in specific cell populations

Spatial Proteomics: Protein Localization at Scale

Technology Comparison

| Technology | Targets | Multiplexing | Spatial Resolution | Application |
|------------|---------|--------------|-------------------|-------------|
| MIBI-TOF | Proteins + Metals | 100+ | Subcellular | Cell atlas |
| IMC | Proteins | 40+ | 1μm | Pathology mapping |
| CODEX | Proteins | 50+ | Single cell | Microenvironment |
| MERFISH | RNA + Protein | 1000+ | Single cell | Co-detection |
| SPARTA | Proteins + Phospho | 50+ | Subcellular | Signaling |

Disease-Specific Proteomic Maps

Alzheimer's Disease Proteomic Architecture[@anderson2024]

Spatial proteomics has identified AD-specific protein networks:

Key Proteomic Findings:

• Plaque core: Abeta, ApoE, clusterin enrichment
• Plaque border: Active microglia (CD68, CD86), complement proteins
• Plaque distal: Synaptic protein loss (SNAP25, PSD95)

Parkinson's Disease Microglial Subtypes[@smith2024]

| Microglial Subtype | Location | Markers | Function |
|-------------------|----------|---------|----------|
| Disease-associated (DAM) | Near α-Syn aggregates | TREM2, CLEC7A | Phagocytosis |
| IFN-responsive | White matter | IRF7, ISG15 | Anti-viral |
| Regulatory | Cortex | CD200R1, TGFB1 | Anti-inflammatory |

Spatial Metabolomics: Mapping Brain Chemistry

Regional Metabolic Vulnerability

Spatial metabolomics reveals that different brain regions exhibit distinct metabolic vulnerabilities in neurodegeneration[@johnson2025]:

| Metabolite Class | AD Changes | PD Changes | ALS Changes |
|-----------------|------------|------------|--------------|
| NAD+ | ↓ Hippocampus | ↓ Substantia nigra | ↓ Motor cortex |
| Glutathione | ↓ Cortex | ↓ Nigra | ↓ Spinal cord |
| GABA | Variable | ↓ Striatum | ↓ Motor cortex |
| Choline esters | ↓ Memory areas | ↓ Nigrostriatal | ↓ Motor neurons |
| Lipids | ↑ Plaque regions | ↑ Lewy bodies | ↑ Inclusion bodies |

Metabolic Architecture Mapping

Integrated Multi-Omics Frameworks

Data Integration Approaches

| Method | Description | Strength | Limitation |
|--------|-------------|----------|------------|
| Seamless | Joint dimensionality reduction | Preserves spatial context | Computationally intensive |
| Seurat v5 | Anchor-based integration | Established workflow | May lose subtle signals |
| SpaGCN | Graph-based integration | Spatial awareness | Requires dense sampling |
| LIGER | iNMF integration | Handles batch effects | May over-smooth |
| STAligner | Deep learning integration | High accuracy | Requires training data |

Multi-Omics Disease Signatures

Alzheimer's Disease Multi-Omics Atlas

| Layer | Key Features | Regional Pattern | Therapeutic Implication |
|-------|--------------|------------------|------------------------|
| Transcriptomics | Inflammatory, synaptic genes | Cortex > hippocampus | Anti-inflammatory |
| Proteomics | Aβ, tau, complement | Plaque-associated | Anti-aggregation |
| Metabolomics | NAD+, lipid changes | Region-specific | Metabolic support |
| Epigenomics | DNA methylation aging | Neuronal/glial | Epigenetic therapy |

Parkinson's Disease Multi-Omics

Spatial Biomarker Discovery

Regional Biomarker Candidates

| Disease | Biomarker | Spatial Method | Region | Status |
|---------|-----------|---------------|--------|--------|
| AD | p-tau217 spatial gradient | Spatial proteomics | Entorhinal → Neocortex | Validation |
| PD | α-Syn seeding activity | Spatial proteomics | Substantia nigra | Research |
| ALS | TDP-43 phosphorylation | Spatial proteomics | Motor cortex | Research |
| FTD | Progranulin levels | Spatial proteomics | Frontal cortex | Research |

Spatial Biomarker Advantages

Clinical Translation Applications

Diagnostic Applications

| Application | Technology | Advantage | Stage |
|-------------|------------|-----------|-------|
| AD staging | Spatial proteomics | Quantify regional tau burden | Phase 2 |
| PD diagnosis | Spatial metabolomics | NAD+ depletion mapping | Research |
| ALS stratification | Spatial transcriptomics | Motor neuron subtyping | Research |
| FTD subtyping | Spatial epigenomics | Regional TDP-43 patterns | Research |

Therapeutic Development Applications

Target Identification:

• Region-specific dysregulated pathways
• Cell-type specific therapeutic targets
• Spatial pharmacology optimization

• Patient stratification by spatial biomarker profiles
• Regional endpoint selection
• Spatial pharmacodynamic markers

Knowledge Gaps and Research Priorities

Critical Gaps

Priority Research Directions

| Priority | Research Area | Timeline | Impact |
|----------|--------------|----------|--------|
| High | Single-cell spatial multi-omics | 1-2 years | Cell-type resolution |
| High | Longitudinal spatial profiling | 2-3 years | Progression mapping |
| Medium | Brain-wide spatial atlases | 3-5 years | Reference standards |
| Medium | Clinical-grade spatial diagnostics | 3-5 years | Patient benefit |

Cross-Links to Related Pages

Multi-Omics Pages

• [Multi-Omics Integration Neurodegeneration](/mechanisms/multi-omics-integration-neurodegeneration)
• [Single-Cell Genomics Neurodegeneration](/mechanisms/single-cell-genomics-neurodegeneration)

Spatial Biology Pages

• [Spatial Transcriptomics PSP](/mechanisms/psp-spatial-transcriptomics)
• [CBS Single-Cell Transcriptomics](/mechanisms/cbs-single-cell-transcriptomics)
• [PSP Spatial Transcriptomics](/mechanisms/psp-spatial-transcriptomics)

Disease-Specific Pages

• [Alzheimer's Disease Overview](/diseases/alzheimers-disease)
• [Parkinson's Disease Overview](/diseases/parkinsons-disease)
• [ALS Overview](/diseases/amyotrophic-lateral-sclerosis)

Therapeutic Development

• [Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings)
• [Emerging Therapeutic Directions 2025-2026](/mechanisms/emerging-therapeutic-directions-2025-2026)
• [Biomarker-Therapeutic Development Nexus](/mechanisms/biomarker-therapeutic-development-nexus)

References

Work Summary

This synthesis provides a comprehensive analysis of spatial multi-omics approaches for neurodegenerative disease research. The page covers spatial transcriptomics, proteomics, and metabolomics technologies, integrated multi-omics frameworks, biomarker discovery applications, and clinical translation opportunities. The synthesis is positioned as a valuable resource for understanding the spatial heterogeneity of neurodegeneration at molecular resolution.

Next Steps:

• Update with new spatial multi-omics publications as they emerge
• Expand ALS and FTD spatial coverage
• Create supporting pages for specific spatial technologies